Detection of Mycoplasma Pneumoniae

NCT02511262 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 471

Last updated 2016-02-08

No results posted yet for this study

Summary

The objective of this Clinical Trial is to define the methods to be used to document that illumigene® Mycoplasma Direct meets its intended use claims, using the illumipro instrument, with throat swab samples collected from symptomatic patients.

Conditions

  • Mycoplasma Pneumoniae

Interventions

DEVICE

illumigene® Mycoplasma Direct, illumipro-10

DNA amplification assay

Sponsors & Collaborators

  • Meridian Bioscience, Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511262 on ClinicalTrials.gov